Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Melanoma 7Carcinoma, Non-Small-Cell Lung 7Colorectal Neoplasms 6Stomach Neoplasms 5Pancreatic Neoplasms 5Carcinoma, Renal Cell 5Uterine Cervical Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Rectal Neoplasms 4Neoplasms 4Nasopharyngeal Carcinoma 4Neoplasm Metastasis 3Endometrial Neoplasms 3Triple Negative Breast Neoplasms 2Skin Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Glioblastoma 2Esophageal Squamous Cell Carcinoma 2Advanced Solid Tumors 2von Hippel-Lindau Disease 1Thyroid cancer, follicular 1Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Stomach Adenocarcinoma 1Solid Tumors 1Solid Tumor, Adult 1Solid Tumor 1

Interventions

Cyclophosphamide 13Prednisone 10N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 9Doxorubicin 9Vincristine 8Azacitidine 6romidepsin 5Gemcitabine 5Brentuximab Vedotin 5fludarabine 4Etoposide 4Dexamethasone 4pembrolizumab 3belinostat 3Lenalidomide 3Biopsy 310-propargyl-10-deazaaminopterin 3tazemetostat 2ruxolitinib 2ixazomib 2duvelisib 2Nivolumab 2Bendamustine Hydrochloride 2venetoclax 1tislelizumab 1thymoglobulin 1spartalizumab 1somatostatin, cyclic hexapeptide(Phe-Phe-Trp-Lys-Thr-Phe)- 1sodium-iodide symporter 1sintilimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Peripheral × spartalizumab × 1 year × Clear all
NCT05182957 2026-05-01

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

The First Affiliated Hospital of Soochow University

Phase 2 Recruiting
31 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡